Probiotic yogurt improves antioxidant status in type 2 diabetic patients

Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Nutrition (Impact Factor: 3.05). 11/2011; 28(5):539-43. DOI: 10.1016/j.nut.2011.08.013
Source: PubMed

ABSTRACT Oxidative stress plays a major role in the pathogenesis and progression of diabetes. Among various functional foods with an antioxidant effect, probiotic foods have been reported to repress oxidative stress. The objective of this clinical trial was to assess the effects of probiotic and conventional yogurt on blood glucose and antioxidant status in type 2 diabetic patients.
Sixty-four patients with type 2 diabetes mellitus, 30 to 60 y old, were assigned to two groups in this randomized, double-blind, controlled clinical trial. The patients in the intervention group consumed 300 g/d of probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 and those in the control group consumed 300 g/d of conventional yogurt for 6 wk. Fasting blood samples, 24-h dietary recalls, and anthropometric measurements were collected at the baseline and at the end of the trial.
Probiotic yogurt significantly decreased fasting blood glucose (P < 0.01) and hemoglobin A1c (P < 0.05) and increased erythrocyte superoxide dismutase and glutathione peroxidase activities and total antioxidant status (P < 0.05) compared with the control group. In addition, the serum malondialdehyde concentration significantly decreased compared with the baseline value in both groups (P < 0.05). No significant changes from baseline were shown in insulin concentration and erythrocyte catalase activity within either group (P > 0.05).
The consumption of probiotic yogurt improved fasting blood glucose and antioxidant status in type 2 diabetic patients. These results suggest that probiotic yogurt is a promising agent for diabetes management.

Download full-text


Available from: Aziz Homayouni, Aug 23, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The effects of the functional rice cultivars giant embryo and Aranghyangchal on the body weight and lipid metabolism in male C57BL/6N mice under high fat diet conditions were investigated. The animals were randomly placed into four dietary groups: normal control (NC group), high fat (HF group), and high fat supplemented with giant embryo (HF-GE group) or Aranghyangchal (HF-AR group). After 8weeks, a marked increase in the body weight and plasma triglyceride and total cholesterol concentrations were found in the HF mice relative to the control group. However, the addition of the functional rice samples in the high fat diet reduced the body weight gain and significantly decreased the lipid levels through inhibition of lipogenesis and regulation of adipokine production. The results demonstrate that the functional rice grains giant embryo and Aranghyangchal may both be useful as biomaterials in the development of functional food with therapeutic potential against high fat diet-induced hyperlipidemia.
    06/2013; 16(2). DOI:10.1007/s12892-013-0055-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous clinical trials indicate that probiotic consumption may improve blood glucose control, however, results from randomized trials on glycemic control have been inconsistent. To investigate the effects of probiotics on glycemic control in a systematic review and meta-analysis of randomized controlled trials. PubMed, Embase, Cochrane Library, and through October 2014. Two independent reviewers extracted relevant data and assessed study quality and risk of bias. Data were pooled using a random-effects model and expressed as mean differences (MD) with 95% CI. Heterogeneity was assessed (Cochran Q-statistic) and quantified (I2). Seventeen randomized controlled trials were included, in which 17 fasting blood glucose (n = 1105), 11 fasting plasma insulin (n = 788), 8 homeostasis model assessment of insulin resistance (n = 635) comparisons were reported. Probiotic consumption, compared with placebo, significantly reduced fasting glucose (MD = -0.31 mmol/L; 95% CI 0.56, 0.06; p = 0.02), fasting plasma insulin (MD = -1.29 μU/mL; 95% CI -2.17, -0.41; p = 0.004), and HOMA-IR (MD = 0.48; 95% CI -0.83, -0.13; p = 0.007). Probiotic consumption may improve glycemic control modestly. Modification of gut microbiota by probiotic supplementation may be a method for preventing and control hyperglycemia in clinical practice.
    PLoS ONE 07/2015; 10(7):e0132121. DOI:10.1371/journal.pone.0132121 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Probiotics produce a beneficial impact on the host by improving the endogenous flora. It has been advocated that nonpathogenic bacteria like Lactobacillus and Bifidobacterium may undergo antagonistic interactions with other bacterial strains and can be used to control pathogenic bacteria. Novel modes of therapeutic and prophylactic interventions are based on their consumption either alone or in combination with prebiotics. Usefulness of probiotics has been implicated in allergies, cancer, AIDS, and respiratory and urinary tract infections. In this review we have listed various findings suggesting their benefits in alleviating symptoms associated with aging, fatigue, and autism. Newer claims indicating their role in reducing the risks of osteoporosis, obesity, and possibly type 2 diabetes are also discussed. Considering the wide array of such activities, the present review comprehensively elaborates upon the proposed benefits of probiotics. The concept of synbiotics, a combination of probiotics and prebiotics beneficially affecting the survival and implantation of such live organisms, is also discussed. Available probiotic strains, their commercial preparations, and newer approaches to improve the efficacy and overcome limitations of the therapy are also discussed in relation to the future of probiotic therapy. Considering that the purported claims about disease risk reduction are tentative, the review also encompasses various aspects regarding the safety of probiotics and their possible future role in disease prevention.
    Journal of medicinal food 05/2009; 12(2):219-35. DOI:10.1089/jmf.2007.0544 · 1.70 Impact Factor
Show more